Dr. Etienne Mahe
Etienne Mahe, MD, MSc, is an hematological pathologist based in Calgary, Alberta, Canada. Dr. Mahe has specialist certificates from the Royal College of Physicians & Surgeons of Canada in both Anatomical and Hematological pathology, and is a diplomate of the American Board of Pathology. Dr. Mahe completed his medical degree and residency at McMaster University, as well as a research based master’s degree in pathology at the University of Toronto. Dr. Mahe is a local leader in molecular hematology, with a significant interest in next-generation sequencing. Dr. Mahe’s primary research interests relate to T- and B-cell clonality technologies and assay development. Dr. Mahe is actively involved in medical education, including the coordination of undergraduate teaching. Dr. Mahe is the secretary-treasurer of the Alberta Section of Laboratory Medicine and is a member of the College of American Pathologists’ Hematology and Clinical Microscopy Committee.
The biology and classification of hematolymphoid entities is highly complex, raising challenges for residents and practicing pathologists not routinely faced with a depth and breadth of experience in this area. The aim of this session is to present a simplified approach to the vast spectrum of lymphoproliferative disorders (focusing on the neoplastic entities), with care to highlight recent changes to the WHO classification. This session will review the basic morphological patterns of the most common entities, with a focus on formulating an approach to ancillary studies based on differential morphological features. Given the vast array of ancillary studies available in hematological pathology, this session will distill the most appropriate ancillary resources required to derive a diagnosis and subclassification. Throughout, the session will aim to highlight important clinical features and how other non-IHC/molecular laboratory studies may inform a diagnostic work-up. Important biomarkers will be highlighted, including cytogenetic and molecular biomarkers. Finally, the session will aim to highlight how specific subclassification is relevant from the clinical perspective, especially to inform therapeutic options. This session will be of value to pathology residents and general & anatomical pathologists.
1. Describe the broad classes of lymphoproliferative disorders, with deference to the WHO Classification of Lymphomas
2. Describe the basic morphological patterns characteristic of the most common lymphoproliferative disorders
3. Outline an algorithmic approach to the immunophenotypic work-up of lymphoproliferative disorders
4. Describe the diagnostic and prognostic implications of important biomarkers, including molecular genetic biomarkers
5. Summarize the basic clinical features of lymphoproliferative disorders, the basic treatment approaches, and how specific diagnostic features inform prognosis and therapy
Medical Expert (the integrating role)